When: 10Y Treasury back below 4.20% or Fed pivot signaling 2026 cuts

Then: Re-evaluate to Hold or Overweight

TRIM 30-50% of position, maintain 50-70% core; redeploy trimmed capital to better risk-reward setups; use $148 protective stop on remaining core position

• Forward P/E is 22x but trailing P/E is 35x; entire bull case depends on forward estimates being achieved
• Q2 showed 7% revenue growth and 23% EPS growth, but Q1 2026 grew only 0.2%—not a trend, just one quarter
• November Q3 earnings are a binary verification event; in-line results trigger selling, a miss takes stock to $140
• Expected value math is negative: 0.70×0.7% plus 0.30×(-13.5%) equals -3.56% expected return on full position
• Stock pressing into upper Bollinger Band at $163.51, with August peak at $165.79 forming resistance zone $164-$166
• MACD at +2.14 versus August peak of +5.80 shows momentum divergence, not room to run
• September saw 12% drawdown to $145.83 when RSI hit high levels and momentum crested—setting up similar pattern again
• 09-30 gap-down on 4.65 million shares (highest volume day), followed by 4.7% recovery to $162.33 on declining volume indicates low-liquidity drift into resistance, not institutional breakout conviction
• EMR has 1.21 beta; 10% market correction driven by rate shock means realistic 12-15% EMR drawdown
• 96% probability of no 2026 Fed cuts with 10-year at multi-decade highs makes marginal automation projects discretionary and delayable
• Hold trade real stop-loss is $148 (not $153) after gap consideration, making true risk-reward approximately 1.4 to 1 rather than 3.5 to 1
• Q3 and Q4 book-to-bill data not yet available—insufficient evidence for full position underwriting
• Core fundamentals are real: 26.9% operating margins, 19.9% FCF margins, strengthening balance sheet
• Multiple macro catalysts exist: hot CPI print, Iran escalation driving energy/inflation, soft industrial peer earnings from Honeywell or Fortive, cautious hyperscaler capex

→ vs aggressive: The 35x P/E 'backward-looking' framing is misleading; forward P/E of 22x is an estimate that must be achieved, and Q1 2026's 0.2% growth proves the trajectory is not assured

→ vs aggressive: The 'declining volume is bullish' argument is a reframe; low volume into resistance is low-liquidity drift vulnerable to Bollinger Band rejections, not institutional conviction

→ vs aggressive: MACD at +2.14 versus prior +5.80 peak is a momentum divergence warning, not 'room to run'—the August reference point actually supports taking risk off

→ vs aggressive: The $153 stop on a full position gives back 5.5% before admitting error; proper gap-adjusted stop is $148, making hold risk-reward 1.4 to 1, not 3.5 to 1

→ vs aggressive: EMR beta of 1.21 means 12-15% drawdown in a 10% market correction; rate sensitivity matters for NEW orders even if backlog is visible

→ vs neutral: While technicals (golden cross, MACD, RSI divergence) are bullish as trend, they don't address the asymmetric risk at upper Bollinger Band resistance with no catalyst

Proceed with trim in tranches (one-third at 163-164, one-third at 165-166 on breakout test, remainder held for confirmed breakout or rejection); tighten core stop to 150-152; pre-commit redeployment at 153-155 on 50 SMA pullback; maintain 50-70% core position.

• Technical picture is genuinely bullish: price 12.5% above 200 SMA, golden cross widening, MACD positive for 9 sessions, bullish RSI divergence off September lows
• Forward P/E of 22x implies ~59% earnings growth priced in; trailing P/E of 35x is misleading without forward adjustment
• AspenTech angle is real: 70% gross margin software business within 26.9% operating margin industrial platform
• Current price ~162 pressing upper Bollinger Band at 163.51; verified October 5 high was 164.21, August peak 165.79; RSI at 64, MACD histogram matching prior cycle peak
• Q2 fundamentals strong: 280 bps operating margin expansion, 23% EPS growth, $1.4B debt paydown in single quarter
• ATR of 3.91; current 50 SMA and Bollinger middle band near 156; 3.6 ATRs of drawdown to 148 stop versus 2 ATRs to 156
• Trim in three tranches rather than full 30-50% at once: one-third at 163-164, one-third at 165-166 if breakout test, remainder for confirmed breakout above 166 or rejection
• Tighten protective stop to 150-152 (September consolidation zone and rising 50 SMA) rather than 148; 148 is below structural floor and only relevant in full bear market
• Pre-commit buyback level at 153-155 on 50 SMA with constructive tape, not waiting for 150 in vacuum
• Q1 was 0.2% revenue growth, Q2 was 7%: this trajectory suggests Q3/Q4 confirmation setup rather than fluke
• Company serves process industries, energy infrastructure, hyperscalers, and reshoring-driven manufacturing on multi-year decision horizons; 96% probability of no 2026 cuts is real but backlog doesn't reprice quarterly

→ vs aggressive: Conflating constructive technical setup with obligation to be fully long; using prior cycle's MACD peak of 5.80 (which marked the actual top before 12% drawdown) as evidence of upside is reading the chart upside down; momentum oscillators peak before prices do and by the time RSI hits 70, half the move is already behind you

→ vs conservative: Using Research Manager's static 0.7% upside versus 13.5% downside framing without adjusting for Q2's 280 bps operating margin expansion, 23% EPS growth, and $1.4B debt paydown which changes the fundamental picture; stop at 148 (14 points, 8.6% drawdown) is not anchored to structure—148 is below the structural floor and only matters in a full bear market where being stopped at 148 versus 152 is a rounding error

→ vs conservative: Overstating macro fragility for this specific name; EMR serves multi-year decision horizons and existing backlog doesn't reprice quarterly; equity risk-off events are a legitimate concern but not the same as rate sensitivity of existing franchise